|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ki67 (P < 0.002) and c-erbB-2 (P < 0.0001) correlated well with overall survival (P < 0.0008) and grade (P < 0.038) but not with lymph node status and tumour type. p34cdc2 showed a trend towards a positive correlation with Ki67 (P < 0.058) and a significant negative correlation with receptor status (P < 0.008) but with none of the other parameters examined.
|
9870146 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found a significant upregulation in CCNB1 (1.5-fold), CDC2 (1.4-fold), and MKI67 (1.8-fold) expression in recurrent tumors in comparison with primary tumors (P<0.05).
|
22137483 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
OSU-HDAC42, (i) unlike most HDACIs, elicited a more than five-fold increase in G(2)-phase cells, at 2.5 microM, with G(2) arrest followed by apoptosis; (ii) at 1.0 microM, completely repressed messenger RNA expression of the cell cycle progression gene cdc2; (iii) at low doses (0.25-1.0 microM for 24 hours), induced tumor cell epithelial differentiation, as evidenced by morphology changes and a more than five-fold up-regulation of epithelium-specific cytokeratins; (iv) potently abrogated the growth of numerous ovarian cancer cells, with IC(50) values of 0.5 to 1.0 microM, whereas also remaining eight-fold less toxic (IC(50) of 8.6 microM) to normal ovarian surface epithelial cells; and (v) chemosensitizated platinum-resistant mouse xenografts to cisplatin.
|
19484144 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues was significantly associated with disease-free survival (DFS) in PDAC patients (Log rank <i>P</i>=0.00565, <i>P</i>=0.0357, <i>P</i>=0.00104, and <i>P</i>=0.00121, respectively).
|
30765611 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK1 inhibitor RO3306 in combination with sorafenib treatment significantly decreased tumor growth in PDX tumor models.
|
30083256 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cyclin-dependent kinase 1 (CDK1) orchestrates the transition from the G2 phase into mitosis and as cancer cells often display enhanced CDK1 activity, it has been proposed as a tumor specific anti-cancer target.
|
30045664 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HTMC treatment also led to an inhibition of cell-cycle regulatory proteins phosphorylation of cdc2 (Tyr(15) and Tyr(161)) and Rb (Ser(795) and Ser(807/811)), which was accompanied by the accumulation of tumor suppressor genes p53 and p21.
|
20926293 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Proteins that contribute most strongly to the proteotype-based classification include INPP4B, CDK1, and ERBB2 and are associated with estrogen receptor (ER) status, tumor grade status, and HER2 status.
|
31315058 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CR-LAAO altered the tumor cell expression of DNA repair genes, with two downregulated (XRCC4 and TOPBP1) and three upregulated (ERCC6, RAD52 and CDKN1) genes.
|
29738841 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
|
28426773 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hence, exposing RCC cells to amygdalin inhibited cell cycle progression and tumor cell growth by impairing cdk1 and cyclin B expression.
|
26709398 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The results indicated that the tumor suppressive activity of SASH1 derived from G2/M arrest in A-375 cells, and that the phosphorylation of Cdc2 or the disruption of cyclin B-Cdc2 binding may be responsible for the G2/M arrest.
|
23023727 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, in breast tumors from patients, we found a negative correlation between CDK1 accumulation and βTrCP levels, and a positive correlation with the degree of tumor malignancy.
|
28855742 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Following ex vivo study, viral particles containing small interfering RNA for CDC2 were subsequently injected into xenogeneic graft tumor of nude mice and the weight of human glioma xenografts, survival and resulting phenotypic changes of target gene were investigated.
|
18230152 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
|
30365555 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protein expression was also measured in tumour samples, with markedly variable levels of CDK1 and PLK1 noted.
|
24327015 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increase of the tumor-node-metastasis (TNM) staging of osteosarcoma and the high expression of CDC2 are the risk factors affecting the prognosis of osteosarcoma patients (P<0.05), and Cox regression analysis showed that the expression level of CDC2 was a risk factor affecting the prognosis of osteosarcoma patients (P<0.05).
|
29731906 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, when the percentages of p34cdc2 and mutant-type p53-positive cells in the tumor were high, aneuploidy tended to be present and the clinical stage more advanced.
|
8809331 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, CDK1 inhibition imitated the tumor suppressor activity of miR-769 in CRC cells, and restoration of CDK1 expression partially abolished the tumor-suppressing roles of miR-769 in malignant CRC cells.
|
30588014 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance.
|
26141949 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients with BC, high co-expression of TFCP2L1 and CDK1 was associated with unfavorable clinical characteristics including tumor grade, lymphovascular and muscularis propria invasion, and distant metastasis and was an independent prognostic factor for cancer-specific survival.
|
31709755 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, primary breast cancers carrying p53 mutations and displaying high YAP activity exhibit higher expression levels of cyclin A, cyclin B, and CDK1 genes when compared to wt-p53 tumors.
|
26691213 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review is to recapitulate cyclin B1/CDK1 mediated mitochondrial activities in cell cycle progression and stress response as well as its potential link to reprogram energy metabolism in tumor adaptive resistance.
|
30481564 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show that the recently discovered tumor suppressor pdcd4 represses the transcription of the mitosis-promoting factor cyclin-dependent kinase (CDK)1/cdc2 via upregulation of p21(Waf1/Cip1). p21(Waf1/Cip1) inhibits CDK4/6 and CDK2.
|
15317660 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo studies showed that miR-490-3P transfection suppressed tumor development and CDK1, Bcl-xL, MMP2/9 expression while inducing P53 expression.
|
25819031 |
2015 |